Life sciences · Journal article

Management of nausea and vomiting with claudin 18.2-targeted therapy in upper gastrointestinal cancer

ESMO Gastrointestinal Oncology · August 17, 2026

Expert Guidance Why this matters to you Expert discussion

A consensus or society position rather than new primary data.

AI Summary

This is a panel discussion among three experienced gastrointestinal oncologists addressing practical clinical management of nausea and vomiting in patients receiving claudin 18.2-targeted therapy for upper gastrointestinal cancer. It provides expert guidance rather than original trial evidence and does not report efficacy data, outcomes, or comparative results.

What was studied

Journal article. Patients with upper gastrointestinal cancer receiving claudin 18.2-targeted therapy. China, Japan, Germany (institutional affiliations of panelists).

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

Clinicians may use this expert perspective to inform management strategies for nausea and vomiting during claudin 18.2-targeted therapy, though the discussion itself does not present underlying trial data or outcome measures.

Plain-language summary

This is an expert panel discussion on practical management of adverse effects from a specific therapy, not a study reporting original evidence on efficacy or safety.

Study design

As stated by the source record.

SettingChina, Japan, Germany (institutional affiliations of panelists)

Clinical bottom line

Caveats

Source does not report study data, effect sizes, or numerical outcomes on nausea/vomiting incidence or management efficacy.
No comparative analysis or evidence synthesis is provided.
Specific management recommendations and their evidence base are not transcribed in the source text.
The clinical content and conclusions of the discussion are not detailed enough to evaluate the strength of underlying evidence.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

No study design; this is a discussion format, not original research.

Directness

moderate

Addresses a clinically relevant adverse effect management question in the target population.

Consistency

insufficient

Source does not report comparative data or consistency across studies.

Risk of bias

insufficient

Not applicable; no trial data presented to assess bias.

Sample adequacy

insufficient

No quantitative data or sample size reported.

What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

In this podcast, European Society for Medical Oncology upper gastrointestinal faculty, Prof. Zhouqiao Wu, surgeon in the Department of Gastrointestinal Surgery at Peking University Cancer Hospital & Institute, Beijing, China, presents a discussion between Prof. Kohei Shitara, gastrointestinal medical oncologist at the National Cancer Center Hospital East, Kashiwa, Japan, and Prof. Sylvie Lorenzen, medical oncologist at the Technical University of Munich, Munich, Germany, about the practical management of nausea and vomiting associated with claudin 18.2-targeted therapy in upper gastrointestinal cancer.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

S. LorenzenZ. WuK. Shitara